Abstract:Erianin is a major bisbenzyl compound extracted from Dendrobium chrysotoxum Lindl., an important traditional Chinese herb. In recent years, a growing body of evidence has proved the potential therapeutic effects of erianin on various cancers, including hepatoma, melanoma, non-small-cell lung carcinoma, myelogenous leukemia, breast cancer, and osteosarcoma. Especially, the pharmacological activities of erianin, such as antioxidant and anticancer activity, have been frequently demonstrated by plenty of studies. In this study, we firstly conducted a systematic review on reported anticancer activity of erianin. All updated valuable information regarding the underlying action mechanisms of erianin in specific cancer was recorded and summarized in this paper. Most importantly, based on the molecular structure of erianin, its potential molecular targets were analyzed and predicted by means of the SwissTargetPrediction online server ( http://www.swisstargetprediction.ch ). In the meantime, the potential therapeutic targets of 10 types of cancers in which erianin has been proved to have anticancer effects were also predicted via the Online Mendelian Inheritance in Man (OMIM) database ( http://www.ncbi.nlm.nih.gov/omim ). The overlapping targets may serve as valuable target candidates through which erianin exerts its anticancer activity. The clinical value of those targets was subsequently evaluated by analyzing their prognostic role in specific cancer using Kaplan-Meier plotter ( http://Kmplot.com/analysis/ ) and Gene Expression Profiling Interactive Analysis (GEPIA) ( http://gepia.cancer-pku.cn/ ). To better assess and verify the binding ability of erianin with its potential targets, molecular flexible docking was performed using Discovery Studio (DS). The valuable targets obtained from the above analysis and verification were further mapped to the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway using the Database for Annotation, Visualization and Integrated Discovery (DAVID) ( http://david.abcc.ncifcrf.gov/ ) to explore the possible signaling pathways disturbed/regulated by erianin. Furthermore, the in silico prediction of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties of erianin was also performed and provided in this paper. Overall, in this study, we aimed at 1) collecting all experiment-based important information regarding the anticancer effect and pharmacological mechanism of erianin, 2) providing the predicted therapeutic targets and signaling pathways that erianin might act on in cancers, and 3) especially providing in silico ADMET properties of erianin.

Erianin inhibits human lung cancer cell growth via PI3K /Akt/ mTOR pathway in vitro and in vivo

Erianin regulates programmed cell death ligand 1 expression and enhances cytotoxic T lymphocyte activity

Erianin, a novel dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis

Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways.

Erianin suppresses proliferation and migration of cancer cells in a pyruvate carboxylase-dependent manner

Erianin Suppresses the Development of Acute Myeloid Leukemia Via PPARɑ and Regulating PI3K/AKT Signaling Pathways

Anticancer Activity of Erianin: Cancer-Specific Target Prediction Based on Network Pharmacology

Erianin inhibits the oncogenic properties of hepatocellular carcinoma via inducing DNA damage and aberrant mitosis

Erianin Inhibits Indoleamine 2, 3-Dioxygenase - Induced Tumor Angiogenesis

Erianin Inhibits the Growth and Metastasis Through Autophagy-Dependent Ferroptosis in KRASG13D Colorectal Cancer

Erianin suppressed lung cancer stemness and chemotherapeutic sensitivity via triggering ferroptosis

Erianin inhibits the progression of DDP-resistant lung adenocarcinoma by regulating the Wnt/β-catenin pathway and activating the caspase-3 for apoptosis in vitro and in vivo

Erianin inhibits the growth and metastasis through autophagy-dependent ferroptosis in KRAS G13D colorectal cancer

Erianin inhibits oral cancer cell growth, migration, and invasion via the Nrf2/HO-1/ GPX4 pathway

Erianin inhibits the progression of pancreatic cancer by directly targeting AKT and ASK1

Erianin Induces Apoptosis Of Colorectal Cancer Cells Via Activation Of Jnk Signaling Pathways

Erianin Induces G2/M-phase Arrest, Apoptosis, and Autophagy Via the ROS/JNK Signaling Pathway in Human Osteosarcoma Cells in Vitro and in Vivo

Progressive Study of Effects of Erianin on Anticancer Activity

Ott_a_200161 5457..5465

The Anti-Carcinogenesis Properties Of Erianin In The Modulation Of Oxidative Stress-Mediated Apoptosis And Immune Response In Liver Cancer

Erianin inhibits tumor growth by promoting ferroptosis and inhibiting invasion in hepatocellular carcinoma through the JAK2/STAT3/SLC7A11 pathway